Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335268 | 0.87 | DRD2 (0.52) | DRD2SLC6A4SIGMAR1 | |
| SCHEMBL5569217 | 0.87 | SLC6A4 (0.48) | DRD2SLC6A4SIGMAR1 | |
| SCHEMBL5332520 | 0.85 | DRD2 (0.53) | DRD2SLC6A4SIGMAR1HRH3 | |
| SCHEMBL5334230 | 0.84 | DRD2 (0.52) | DRD2SLC6A4SIGMAR1HRH3 | |
| SCHEMBL6300929 | 0.81 | SIGMAR1 (0.54) | DRD2SLC6A4SIGMAR1KDM1A | |
| SCHEMBL6301070 | 0.79 | DRD2 (0.45) | DRD2SLC6A4 | |
| SCHEMBL5564087 | 0.78 | DRD2 (0.50) | DRD2SLC6A4SIGMAR1 | |
| SCHEMBL6214213 | 0.78 | DRD2 (0.50) | DRD2SLC6A4SIGMAR1 | |
| SCHEMBL6214207 | 0.76 | HTR1A (0.48) | DRD2SLC6A4SIGMAR1 | |
| SCHEMBL18872185 | 0.76 | HTR1A (0.53) | DRD2SLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | DRD2 476/4885SLC6A4 972/4885SIGMAR1 266/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | DRD2 476/4885SLC6A4 972/4885SIGMAR1 266/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | DRD2 476/4885SLC6A4 972/4885SIGMAR1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.